The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.

I CarusoL Di GioiaS Di MolfettaM CaporussoA CignarelliG P SoriceL LaviolaFrancesco Giorgino

Published in: Journal of endocrinological investigation (2024)

TZP was associated with an increased risk of specific AE. However, its safety profile was similar to that of GLP-1RA, without increased risk of pancreato-biliary AE, diabetic retinopathy, and medullary thyroid cancer.

Keyphrases

diabetic retinopathy
adverse drug
optical coherence tomography
rheumatoid arthritis
electronic health record
drug induced
disease activity
systemic sclerosis
systemic lupus erythematosus
interstitial lung disease
idiopathic pulmonary fibrosis